- Home
- HMY vs MRNA Comparison
HMY vs MRNA Comparison
Compare HMY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- MRNA
- Stock Information
- Founded
- HMY 1950
- MRNA 2010
- Country
- HMY South Africa
- MRNA United States
- Employees
- HMY N/A
- MRNA N/A
- Industry
- HMY Precious Metals
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HMY Basic Materials
- MRNA Health Care
- Exchange
- HMY Nasdaq
- MRNA Nasdaq
- Market Cap
- HMY 9.4B
- MRNA 10.9B
- IPO Year
- HMY N/A
- MRNA 2018
- Fundamental
- Price
- HMY $14.01
- MRNA $24.28
- Analyst Decision
- HMY Hold
- MRNA Hold
- Analyst Count
- HMY 2
- MRNA 19
- Target Price
- HMY $12.20
- MRNA $43.50
- AVG Volume (30 Days)
- HMY 5.2M
- MRNA 9.3M
- Earning Date
- HMY 01-01-0001
- MRNA 08-01-2025
- Dividend Yield
- HMY 0.99%
- MRNA N/A
- EPS Growth
- HMY 67.74
- MRNA N/A
- EPS
- HMY 1.29
- MRNA N/A
- Revenue
- HMY $4,161,584,110.00
- MRNA $3,078,000,000.00
- Revenue This Year
- HMY $23.01
- MRNA N/A
- Revenue Next Year
- HMY $23.16
- MRNA $10.17
- P/E Ratio
- HMY $11.78
- MRNA N/A
- Revenue Growth
- HMY 20.39
- MRNA N/A
- 52 Week Low
- HMY $7.97
- MRNA $23.15
- 52 Week High
- HMY $18.77
- MRNA $79.96
- Technical
- Relative Strength Index (RSI)
- HMY 44.89
- MRNA 35.47
- Support Level
- HMY $12.58
- MRNA $23.40
- Resistance Level
- HMY $15.58
- MRNA $24.66
- Average True Range (ATR)
- HMY 0.57
- MRNA 1.08
- MACD
- HMY -0.16
- MRNA -0.13
- Stochastic Oscillator
- HMY 39.50
- MRNA 18.06
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.